Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

AMGEN-BIO-FARMACÊUTICA LDA

NIF 502942959
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €6,810,485 95 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €6,810,485 95 contracts
A2 · Late Publication €12,359,793,104 2,271 contracts
Contract published to BASE more than 10 days after the signing date
LOW €12,359,793,104 2,271 contracts
A5 · Threshold Splitting €4,650,844 77 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €4,650,844 77 contracts
A6 · Low Competition €8,043,999 37 contracts
Only one bidder participated in a competitive procedure
MEDIUM €8,043,999 37 contracts
A9 · Abnormal Price Reduction €15,515,999,528 851 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €15,515,999,528 851 contracts
C3 · Missing Mandatory Fields €10,460,671 76 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €10,460,671 76 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

358
€1,603,092,759
75
€649,732,417
290
€580,332,748
27
€573,532,310
286
€570,507,473
82
€563,217,941
42
€562,668,158
163
€557,971,463
34
€557,785,137
37
€539,877,495
234
€527,994,233
19
€508,855,787
20
€494,443,575
36
€487,664,043
179
€486,052,867
19
€482,704,476
84
€477,595,570
61
€475,913,005
17
€466,732,413
21
€461,650,024
Page 1 of 3 · 54 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 2 · 95 contracts

AQUISIÇÃO URGENTE DIVERSOS MEDICAMENTOS
PT · 11954119 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€62,789 2025-10-03
AQUISIÇÃO URGENTE DE VARIOS MEDICAMENTOS
PT · 11978826 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€68,900 2025-09-30
Sotorasib 120mg Comp - 10000018892025
PT · 11877744 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€51,576 2025-08-07
aquisição urgente medicamentos
PT · 12020491 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€67,724 2025-07-01
APREMILASTE - 10000015392025
PT · 11600074 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€25,786 2025-05-27
Aquisição Medicamento Sotorasib 120 mg Comp
PT · 11726381 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€81,048 2025-04-09
VÁRIOS MEDICAMENTOS
PT · 11279412 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€61,032 2025-03-10
VÁRIOS MEDICAMENTOS
PT · 11306751 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€43,704 2025-02-24
Adalimumab
PT · 11409574 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€136,800 2025-01-28
VÁRIOS MEDICAMENTOS
PT · 11195135 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€44,310 2025-01-20
SOTORASIB 120MG COMP
PT · 11080559 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€95,784 2024-08-16
Medicamentos Bevacizumab 25 mg/ml (100mg/4ml e 400mg/16 ml)
PT · 11048257 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€47,684 2024-06-06
10000009762024 - ADALIMUMAB 40MG/ 0.8ML SOL INJ CANETA 0.8 ML
PT · 10797017 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€140,000 2024-03-18
AQUISIÇÃO DO MEDICAMENTO SOTORASIB 120 MG DE FORNECIMENTO EXCLUSIVO DO LABORATÓRIO AMGEN - BIOFARMACÊUTICA
PT · 10554125 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A6 · Low Competition
€95,784 2024-02-05
J1/29/2024 – BEVACIZUMAB - MVASI
PT · 10549238 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€2,483 2023-12-21
MEDICAMENTO EXCLUSIVO AMGEN - SOTORASIB 120 MG
PT · 10331624 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€22,104 2023-10-26
VÁRIOS MEDICAMENTOS
PT · 10246961 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€16,429 2023-08-29
Medicamento Carfilzomib inj ao abrigo do CPA 2021/6 dos SPMS
PT · 10112326 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€56,866 2023-06-15
AD/488/2023 - Medicamento Blinatumumab inj 38 mcg iv
PT · 10936386 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€42,220 2023-05-03
Sotorasib 120mg Comp
PT · 9902250 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€95,784 2023-03-22
Aquisição do medicamento Evolocumab de fornecimento exclusivo do Laboratório Amgen Biofarmacêutica
PT · 9796823 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€28,500 2023-01-26
Evolocumab 140 mg/1 ml Sol inj Caneta 1 ml SC
PT · 9702713 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€6,329 2023-01-13
J1/0108/2023-BEVACIZUMAB MVASI
PT · 9674033 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€7,021 2022-12-28
Ajuste direto para aquisição de A1278, B770, B771, P1400 e T1585 doentes em tratamento, para suprir necessidades na área da saúde.
PT · 9417017 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A9 · Abnormal Price Reduction
€124,140 2022-08-18
Ajuste direto para aquisição de A1278; B770; B771; P1400; T1585; T1633 (doentes em tratamento), para suprir necessidades na área da saúde.
PT · 9351900 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€623,197 2022-06-08
J1/1296/2022-BEVACIZUMAB MVASI
PT · 9211076 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€44,460 2022-04-11
AQUISIÇÃO DO MEDICAMENTO EVOLOCUMAB DE FORNECIMENTO EXCLUSIVO DO LABORATÓRIO AMGEN BIOFARMACÊUTICA
PT · 9021376 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€11,169 2022-02-22
J1/0559/2022-BEVACIZUMAB MVASI - Doentes em tratamento
PT · 9177030 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€22,230 2022-02-15
J1/0325/2022-AC-BEVACIZUMAB MVASI - doentes em tratamento
PT · 9142464 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,500 2022-01-27
J1/0322/2022-AC-Bevacizumab MVASI - doentes em tratamento
PT · 9142456 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€1,237 2022-01-27
J1/2874/2021 - BEVACIZUMAB 100MG/4ML MVASI
PT · 7862248 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€2,475 2021-09-20
MEDICAMENTO EXCLUSIVO AMGEN - EVOLOCUMAB 140 MG1ML SOL INJ CANETA SC
PT · 7541900 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2021-02-23
CHPL - 51005418 Cinacalcet 30 mg comp
PT · 5276543 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€1,122 2018-01-04
Medicamentos Exclusivos dos Laboratórios Amgen 2017
PT · 4582836 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€561 2017-03-01
Cinacalcet 30 mg comp
PT · 2822359 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€140 2016-10-26
Cinacalcet 30 mg comp
PT · 9fc0068480f42c314b95 · Ajuste direto
A2 · Late Publication A1 · Repeat Direct Award
€140 2016-10-26
Cinacalcet 30 mg comp
PT · 2466264 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€280 2016-06-16
Cinacalcet 30 mg comp
PT · 2821356 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€420 2016-05-12
41102916 - Cinacalcet 30 mg comp
PT · 2186698 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€420 2016-02-24
41102916 - Cinacalcet 30 mg comp
PT · 62283a3ebfd756386350 · Ajuste direto
A2 · Late Publication A1 · Repeat Direct Award
€420 2016-02-24
Medicamentos do foro oncológico - com base no CPA 2013/6
PT · 2276080 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2015-10-29
DARBEPOETINA ALFA 500MCG/1ML SC INJ CANETA
PT · 1878260 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,508 2014-07-29
CONTRATO DE AQUISIÇÃO DE DARBEPOETÍNA 500mcg/1ml Caneta
PT · 1316981 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€25,887 2014-07-03
Aquisição de Medicamentos Diversos
PT · 1863968 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€15,187 2014-04-23
Aquisição medicamentos diversos
PT · 1864990 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€6,343 2014-03-21
DARBEPOETINA ALFA 500MCG/1ML SC INJ CANETA
PT · 1704498 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,508 2014-02-26
AS02283/2013 Medicamentos - Denosumab
PT · 896551 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-06-24
61115913 - Denosumab 120 mg sol inj sol Fr 1.7 ml SC
PT · 780364 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€0 2013-06-19
61110813 - Medicamentos (Denosumab 120 mg Sol inj Fr 1.7 ml SC)
PT · 773242 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€0 2013-06-05
61101213 - Medicamentos
PT · 758261 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€0 2013-05-13
Next →
Overview
Total Value Won
€15,678,365,307
Contracts Won
3,288
Score 109055 · CRITICAL RISK
NIF
502942959
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • C.I. [P-8cde]
    Gerente
    since 2014-08-19
  • J.M. [P-2b80]
    Gerente
    since 2011-12-15
  • M.F. [P-d8ab]
    Gerente
    since 2014-02-19
  • M.A. [P-c5e7]
    Gerente
    since 2010-10-12
  • P.F. [P-8896]
    Gerente
    since 2023-05-30
  • R.K. [P-36e2]
    Gerente
    since 2009-03-20
  • T.J. [P-d7ae]
    Gerente
    since 2009-03-20
  • T.G. [P-8f1f]
    Gerente
    since 2019-04-02
  • A.S. [P-e73b]
    Gerente
    2020-11-26 → 2023-05-30
  • A.H. [P-655e]
    Gerente
    2013-11-04 → 2014-02-19
  • C.I. [P-8cde]
    Gerente
    2015-07-23 → 2017-11-08
  • F.C. [P-6013]
    Gerente
    2012-11-27 → 2014-08-19
  • J.J. [P-2047]
    Gerente
    2009-10-30 → 2010-10-12
  • J.G. [P-cafe]
    Gerente
    2017-11-08 → 2020-11-26
  • M.F. [P-d8ab]
    Gerente
    2015-07-23 → 2025-04-14
  • M.A. [P-c5e7]
    Gerente
    2012-11-27 → 2013-11-04
  • O.M. [P-bcaa]
    Gerente
    2010-10-12 → 2011-12-15
  • R.P. [P-fb9d]
    Gerente
    2013-11-04 → 2014-08-19
  • R.W. [P-c2d8]
    Gerente
    2012-11-27 → 2013-11-04
  • R.D. [P-4892]
    Gerente
    2009-03-20 → 2009-10-30
  • T.J. [P-d7ae]
    Gerente
    until 2010-10-12
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned